<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85626">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851850</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067</org_study_id>
    <nct_id>NCT01851850</nct_id>
  </id_info>
  <brief_title>Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial</brief_title>
  <official_title>Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by
      subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for
      additional three years.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>off periods</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of &quot;off&quot; periods during the day without worsening dyskinesia.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opicapone</intervention_name>
    <description>25mg or 50mg once per day</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis with PD

          -  subjects who are willing to participate in the trial.

          -  subjects who participated in the BIA 9-1067-302 clinical trial.

        Exclusion Criteria:

          -  subjects who didn't take part at the BIA 9-1067-302 clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruth Djaldetti, Professor</last_name>
    <phone>972-3-9378218/9</phone>
    <email>ruthdjal@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaniv Roditi, MSc</last_name>
    <phone>972-39236843</phone>
    <email>yar@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tiqva</city>
        <state>Hamerkaz</state>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ruth Djaldetti, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>May 10, 2013</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD</keyword>
  <keyword>Off periods</keyword>
  <keyword>quality of life</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>end-off-dose motor fluctuations</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
